SEARCH

SEARCH BY CITATION

References

  • Adesanya CO, Yousuf KA, Co C, Gaur S, Ahmed S, Pothoulakis A et al. (2008). Is wider worse? QRS duration predicts cardiac mortality in patients with right bundle branch block. Ann Noninvasive Electrocardiol 13: 165170.
  • Berecki G, Wilders R, de Jonge B, van Ginneken AC, Verkerk AO (2010). Re-evaluation of the action potential upstroke velocity as a measure of the Na+ current in cardiac myocytes at physiological conditions. PLoS ONE 5: e15772.
  • Choi KH, Lee KU (2008). Serial monitoring of lead aVR in patients with rolonged unconsciousness following tricyclic antidepressant overdose. Psychiatry Investig 5: 247250.
  • Cordes J, Li C, Dugas J, Austin-LaFrance R, Lightbown I, Engwall M et al. (2009). Translation between in vitro inhibition of the cardiac Nav1.5 channel and preclinical and clinical QRS widening. J Pharm Tox Meth 60: 221. (abstract).
  • Desai AD, Yaw TS, Yamazaki T, Kaykha A, Chun S, Froelicher VF (2006). Prognostic significance of quantitative QRS duration. Am J Med 119: 600606.
  • Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH et al. (1991). Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 324: 781788.
  • Frank R, Hargreaves R (2003). Clinical biomarkers in drug discovery and development. Nat Drug Disc Rev 2: 566580.
  • Gintant G (2011). An evaluation of hERG current assay performance: translating preclinical safety studies to clinical QT prolongation. Pharmacol Ther 129: 109119.
  • Hanson LA, Bass AS, Gintant G, Mittelstadt S, Rampe D, Thomas K (2006). ILSI-HESI cardiovascular safety subcommittee initiative: evaluation of three non-clinical models of QT prolongation. J Pharmacol Toxicol Meth 54: 116129.
  • Harmer AR, Abi-Gerges N, Easter A, Woods A, Lawrence CL, Small BG et al. (2008). Optimisation and validation of a medium-throughput electrophysiology-based hNav1.5 assay using IonWorks. J Pharmacol Toxicol Meth 57: 3041.
  • Harmer AR, Valentin J-P, Pollard CE (2011). On the relationship between block of the cardiac Na+ channel and drug-induced prolongation of the QRS complex. Br J Pharmacol 164: 260273.
  • Heath BM, Cui Y, Worton S, Lawton B, Ward G, Ballini E et al. (2011). Translation of flecainide- and mexiletine-induced cardiac sodium channel inhibition and ventricular conduction slowing from nonclinical models to clinical. J Pharmacol Toxicol Meth 63: 258268.
  • Hondeghem LM, Katzung BG (1977). Time- and voltage-dependent interactions of antiarrhythmic drugs with cardiac sodium channels. Biochim Biophys Acta 472: 373373.
  • Hultén BA, Heath A, Knudsen K, Nyberg G, Starmark JE, Mårtensson E (1992). Severe amitriptyline overdose: relationship between toxicokinetics and toxicodynamics. J Toxicol Clin Toxicol 30: 171179.
  • Johns JA, Anno T, Bennett PB, Snyders DJ, Hondeghem LM (1989). Temperature and voltage dependence of sodium channel blocking and unblocking by O-demethyl encainide in isolated guinea pig myocytes. J Cardiovasc Pharmacol 13: 826835.
  • Lu HR, Rohrbacher J, Vlaminckx E, Van Ammel K, Yan GX, Gallacher DJ (2010). Predicting drug-induced slowing of conduction and pro-arrhythmia: identifying the ‘bad’ sodium current blockers. Br J Pharmacol 160: 6076.
  • Luliano S, Fisher SG, Karasik PE, Fletcher RD, Singh SN (2002). QRS duration and mortality in patients with congestive heart failure. Am Heart J 143: 10851091.
  • Murray KT, Anno T, Bennett PB, Hondeghem LM (1990). Voltage clamp of the cardiac sodium current at 37 degrees C in physiologic solutions. Biophys J 57: 607613.
  • Nattel S (1985). Frequency-dependent effects of amitriptyline on ventricular conduction and cardiac rhythm in dogs. Circulation 72: 898906.
  • Penniman JR, Kim DC, Salata JJ, Imredy JP (2010). Assessing use-dependent inhibition of the cardiac Na(+/-) current (I(Na)) in the PatchXpress automated patch clamp. J Pharmacol Toxicol Meth 62: 107118.
  • Pugsley MK (2002). Antiarrhythmic drug development: historical review and future perspective. Drug Dev Res 55: 316.
  • Ranger S, Nattel S (1995). Determinants and mechanisms of flecainide-induced promotion of ventricular tachycardia in anesthetized dogs. Circulation 92: 13001311.
  • Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S et al. (2003). Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 58: 3245.
  • Sadanaga T, Ogawa S, Okada Y, Tsutsumi N, Iwanaga S, Yoshikawa T et al. (1993). Clinical evaluation of the use-dependent QRS prolongation and the reverse use-dependent QT prolongation of class I and class III antiarrhythmic agents and their value in predicting efficacy. Am Heart J 126: 114121.
  • Shah RR (2006). Can pharmacogenetics help rescue drugs withdrawn from the market? Pharmacogenomics 7: 889908.
  • Shaw RM, Rudy Y (1997). Ionic mechanisms of propagation in cardiac tissue. Roles of the sodium and L-type calcium currents during reduced excitability and decreased gap junction coupling. Circ Res 81: 727741.
  • Sotoodehnia N, Isaacs A, de Bakker PI et al. (2010). Common variants in 22 loci are associated with QRS duration and cardiac ventricular conduction. Nat Genet 42: 10681076.
  • Trepakova ES, Koerner J, Pettit SD, Valentin JP (2009). HESI Pro-Arrhythmia Committee. A HESI consortium approach to assess the human predictive value of non-clinical repolarization assays. J Pharmacol Toxicol Meth 60: 4550.
  • US Food & Drug Administration (2005a). Guidance for Industry: S7B Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals. http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm129122.pdf (accessed 26 May 2011).
  • US Food & Drug Administration (2005b). Guidance for Industry: Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs (E14). http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM129357.pdf (accessed 26 May 2011).
  • US Food & Drug Administration Drug Safety Communication (2010). FDA recommends against the continued use of propoxyphene. http://www.fda.gov/Drugs/DrugSafety/ucm234338.htm (accessed 26 May 2011).
  • Wang DW, Nie L, George AL Jr, Bennett PB (1996). Distinct local anesthetic affinities in Na+ channel subtypes. Biophys J 70: 17001708.